Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China
— Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas — Junshi will continue to be responsible for the promotion of other indications in core areas –The companies will continue to explore business collaborations in overseas markets including emerging markets SHANGHAI, […]
Read more